BEIGENE-BGB-11417-105
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination with Dexamethasone and Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and t(11;14)
CHIMAGEN-CMG1A46-US01
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2, First in Human, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Triple-Specific T-Cell Engager 1A46 in Adult Patients with Advanced CD20 and/or CD19 Positive B-Cell Hematologic Malignancies
DISC-0974-102
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2a Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia
GENMAB-GCT3014-01
Phase I/II
OPEN TO ACCRUAL
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
HMP-2020-306-GLOB1
Phase I
OPEN TO ACCRUAL *
A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations
IIT-ATALLAH-MCW-XEN21
Phase I
OPEN TO ACCRUAL
MCW-XEN21: A Phase 1 Study of XmAb18968 (CD3-CD38) for the Treatment of Patients with Relapsed/Refractory CD38 Positive Acute Leukemia and T Cell Lymphoblastic Lymphoma
JNJ-75276617ALE1001
Phase I
OPEN TO ACCRUAL
A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia
KRONOS-KB-LANRA-1001
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib (LANRA) in Combination with the FLT3 Inhibitor Gilteritinib, in Patients with FLT3-Mutated Relapsed or Refractory AML
MEI-ME-522-001
Phase I
OPEN TO ACCRUAL
A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B-cell Malignancies or Acute Myeloid Leukemia after Failure of Prior Standard Therapies and Voruciclib in Combination with Venetoclax in Subjects with Relapsed and/or Refractory Acute Myeloid Leukemia
TAKEDA-TAK-981-1503
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination with Monoclonal Antibodies in Adult Patients with Relapsed and/or Refractory Multiple Myeloma
TENEOBIO-TENEOTWO-TNB486-001
Phase I
OPEN TO ACCRUAL
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
XENCOR-XMAB13676-01
Phase I
OPEN TO ACCRUAL
A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 (Plamotamab) in Patients with CD20-Expressing Hematologic Malignancies